Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381628 · ClinicalTrials.gov registry record
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 59
- Enrollment target
NCT00381628: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT00381628 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381628 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
Study Hypothesis: We hypothesize that cellular markers from nasal epithelial cells and blood lymphocytes can serve as potential biomarkers reflect the underlying inflammatory state of the lung and will be helpful in determining the presence of a CF pulmonary exacerbation and its overall severity.
Primary Outcome
Blood and sputum samples for general science research collaborators
Interventions
- PROCEDURE epithelial cells and blood lymphocyte extraction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-09 |
| Est. Completion | 2011-09 |
What the finished NCT00381628 record still lists
NCT00381628 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which epithelial cells and blood lymphocyte extraction is the first listed.
NCT00381628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00381628 about?
NCT00381628 is a clinical study titled "Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations". Study Hypothesis: We hypothesize that cellular markers from nasal epithelial cells and blood lymphocytes can serve as potential biomarkers reflect the underlying inflammatory state of the lung and will be helpful in determining the presence of a CF pulmonary exacerbation and its overall severity.
What is the current status of trial NCT00381628?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2006-09. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00381628?
The interventions under investigation include: epithelial cells and blood lymphocyte extraction (PROCEDURE).
Who is sponsoring clinical trial NCT00381628?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia